Allarity Therapeutics, Inc.
Business
Allarity Therapeutics is a clinical-stage precision medicine company developing stenoparib, a dual PARP and tankyrase inhibitor, for platinum-resistant ovarian cancer and small cell lung cancer. The company's proprietary Drug Response Predictor (DRP®) platform identifies gene expression signatures to match patients with responsive therapeutics. Stenoparib is in Phase 2 trials. The company relies on third-party contract manufacturers and plans eventual commercialization partnerships.
Summary from 10-K filed 2026-03-30
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 320,000 | 0 | — | — | — | |
| Research and development | 7 | 6 | 7 | 7 | 14 | |
| Impairment of intangible assets | 0 | 10 | 0 | 18 | — | |
| General and administrative | 6 | 11 | 10 | 10 | 12 | |
| Total operating expenses | 13 | 27 | 17 | 34 | 27 | |
| Loss from operations | −13 | −27 | −17 | −34 | −27 | |
| Interest income | 801,000 | 533,000 | 22,000 | 30,000 | — | |
| Interest expenses | −185,000 | −653,000 | −498,000 | — | — | |
| Foreign exchange gains (losses) | 757,000 | −212,000 | 133,000 | −913,000 | −95,000 | |
| Change in fair value adjustment of warrant derivative liabilities | 1,000 | 3 | 10 | — | — | |
| Total other income | 1 | 2 | 5 | 17 | 41,000 | |
| Loss before income tax expense (benefit) | −11 | −25 | −12 | −18 | — | |
| Income tax expense (benefit) | 0 | −381,000 | 83,000 | 2 | −133,000 | |
| Net loss | −11 | −25 | −12 | −16 | −27 | |
| Net loss attributable to common stockholders | −11 | −25 | −20 | −21 | — | |
| Net loss per common share, basic and diluted (in dollars per share) | −0.78 | −15.65 | −6,031 | −3,093 | −4.19 | |
| Weighted average common shares outstanding, basic and diluted (in shares) | 14 | 2 | 3,385 | 6,805 | 6 | |
| Change in cumulative translation adjustment | −667,000 | 57,000 | 300,000 | −121,000 | — | |
| Total comprehensive loss | −12 | −24 | −12 | −16 | −29 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2022 2022-09-30 |
|---|---|---|---|---|---|---|
| Cash | 15 | 20 | 166,000 | — | — | |
| Receivables from ATM sales | 0 | 1 | 0 | — | — | |
| Other current assets | 265,000 | 115,000 | 209,000 | 2 | — | |
| Prepaid expenses | 2 | 507,000 | 781,000 | 591,000 | — | |
| Tax credit receivable | 866,000 | 770,000 | 815,000 | 789,000 | — | |
| Total current assets | 18 | 22 | 2 | 5 | — | |
| Property, plant and equipment, net | 330,000 | 309,000 | 20,000 | 21,000 | — | |
| Total assets | 18 | 23 | 12 | 15 | — | |
| Accounts payable | 4 | 4 | 8 | 6 | 5 | |
| Accrued expenses and other current liabilities | 3 | 5 | 1 | 2 | — | |
| Warrant derivative liability | 0 | 1,000 | 3 | 374,000 | — | |
| Income taxes payable | 81,000 | 74,000 | 59,000 | 41,000 | — | |
| Convertible promissory note and accrued interest | 1 | 1 | 1 | — | — | |
| Total current liabilities | 8 | 11 | 14 | 11 | — | |
| Total liabilities | 8 | 11 | 15 | 13 | — | |
| Commitments and contingencies (Note 14) | — | — | — | — | — | |
| Common stock, $0.0001 par value (250,000,000 shares authorized); 19,030,619 and 7,302,797 shares issued and 16,080,980 and 7,302,797 outstanding at December 31, 2025, and December 31, 2024, respectively | 3,000 | 1,000 | 0 | — | — | |
| Additional paid-in capital | 144 | 131 | 90 | 83 | — | |
| Accumulated other comprehensive loss | −1 | −354,000 | −411,000 | −721,000 | — | |
| Accumulated deficit | −130 | −119 | −94 | −83 | — | |
| Treasury stock, at cost; 2,949,639 shares | −3 | 0 | — | — | — | |
| Total stockholders equity | 10 | 12 | −3 | −113,000 | — | |
| Total liabilities and stockholders equity | 18 | 23 | 12 | 15 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | −13,000 | 9,000 | — | — | — | |
| Intangible asset impairment | 0 | 10 | 0 | — | — | |
| Common stock issued for services | −200,000 | −336,000 | — | — | — | |
| Stock-based compensation expense | 482,000 | 71,000 | −71,000 | 2 | 6 | |
| Unrealized foreign exchange gain | 1 | −126,000 | −179,000 | 450,000 | 95,000 | |
| Non-cash interest expense | 185,000 | 230,000 | 464,000 | 138,000 | — | |
| Deferred income taxes | 0 | −446,000 | 97,000 | — | — | |
| Other current assets | −150,000 | 94,000 | 1 | −1 | −330,000 | |
| Unearned revenue | 0 | 207,000 | 0 | — | — | |
| Tax credit receivable | −96,000 | 45,000 | −26,000 | — | — | |
| Prepaid expenses | −2 | 274,000 | −190,000 | −618,000 | 130,000 | |
| Accounts payable | −1 | −4 | 2 | 6 | −1 | |
| Accrued liabilities | −3 | 4 | 43,000 | −5 | 7 | |
| Income taxes payable | 7,000 | 15,000 | 18,000 | −19,000 | 8,000 | |
| Net cash used in operating activities | −15 | −17 | −13 | −17 | −15 | |
| Purchase of property and equipment | −8,000 | −298,000 | 0 | −18,000 | — | |
| Net cash used in investing activities | −8,000 | −298,000 | 0 | 791,000 | 1 | |
| Proceeds from 3i promissory notes | 0 | 1 | 1 | 1 | — | |
| Repayment of 3i debt | 0 | −1 | −4 | — | — | |
| Proceeds from ATM sales of common stock, net of issuance costs | 11 | 37 | 0 | — | 32 | |
| Net proceeds from common stock and pre-funded warrant issuance | 3 | 0 | 17 | — | — | |
| Proceeds from issuance of Convertible Redeemable Series A Preferred Stock | 0 | 3 | 1 | — | — | |
| Redemption of Convertible Redeemable Series A Preferred Stock | 0 | −4 | — | — | — | |
| Common stock repurchase | −3 | 0 | — | — | — | |
| Net cash provided by financing activities | 11 | 37 | 11 | −1 | 34 | |
| Net increase (decrease) in cash | −4 | 19 | −2 | −17 | — | |
| Effect of exchange rate changes on cash | −667,000 | 225,000 | −113,000 | −189,000 | −680,000 | |
| Cash paid for interest | 0 | 423,000 | 34,000 | 85,000 | 262,000 | |
| Cash received for interest | 801,000 | 503,000 | — | — | — | |
| Stock issued in conjunction with consulting agreement | 200,000 | 90,000 | 0 | — | 3 | |
| Conversion of Series A Redeemable Preferred Stock to common stock | 0 | 2 | 4 | 1 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Allarity Therapeutics, Inc.'s CIK number?
Allarity Therapeutics, Inc.'s SEC CIK number is 0001860657 (1860657). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Allarity Therapeutics, Inc.'s SEC filings?
All of Allarity Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Allarity Therapeutics, Inc. last report earnings?
Allarity Therapeutics, Inc. (ALLR) most recently filed an earnings 8-K with the SEC on Apr 1, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001213900-26-038061). This is Allarity Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Allarity Therapeutics, Inc.'s most recent earnings 8-K?
Allarity Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed Apr 1, 2026 under accession 0001213900-26-038061. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Allarity Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →